MAGNESIUM SUPPLEMENTATION ON CHILDREN WITH SEVERE PROTEIN ENERGY MALNUTRITION

Khalil MI1, Baki AA2, Akhter N3, Azad MASA4, Zafreen F3, Wahab MA4

Abstract
This hospital based prospective case control study was designed to determine the clinical out come of magnesium supplementation in severely malnourished Bangladeshi children. The study was conducted at Paediatric department of Bangabandhu Sheikh Mujib Medical University (BSMMU) and Ad-din Hospital, Dhaka from June 2006 to December 2006. Total sixty children, divided into two equal groups, were included in the study. Group-I patients were given standard treatment of Protein Energy Malnutrition (PEM) and group-II children were given magnesium supplementation in addition. Serum magnesium level was measured on day-1 and day-12 of admission. Pre-treatment clinical parameters of both groups were comparable. Principal clinical findings were diarrhoea, vomiting, poor appetite, irritability, hypotonia and oedema. Serum magnesium level was low in severely malnourished children. Magnesium supplemented group of patients showed better improvement of appetite, reduction of vomiting and hypotonia. The rate of weight gain was 8.87±3.51 gm/kg/day in group-I and 12.16±6.32 gm/kg/day in group-II, which was significant. Serum magnesium level significantly improved in supplemented group of patients. So, magnesium may be routinely used in the management of malnourished children to hasten recovery.

Introduction
Magnesium depletion has been reported to occur in Protein Energy Malnutrition (PEM) which is evidenced by reduced concentration of magnesium in serum and tissue1-5. Diets in populations are frequently deficient in macronutrients, micronutrients or both6. Magnesium, a common cation in the body plays an essential role in numerous cellular reactions including oxidative phosphorylation, enzymatic reactions, nucleic acid metabolism and protein synthesis7-9.

Magnesium depletion in malnourished children may be asymptomatic or may produce symptoms like anorexia, nausea, muscular weakness, lethargy, tremors, athetoid movement, seizures and psychomotor changes10-11. Deficiency of magnesium is known to compromise primary and secondary immune response and increase tissue susceptibility to lipid peroxidation12-14. Magnesium deficiency rises when demands increases markedly with the resumption of tissue growth during rehabilitation from malnutrition14-3. The catch-up growth associated with recovery from PEM is achieved only if magnesium supply is increased substantially3. The measurement of serum magnesium is a useful test to detect magnesium deficiency in routine clinical practice1. No study was carried out recently in Bangladesh to determine the beneficial effect of magnesium supplementation in malnourished children and magnesium is sporadically given in the management of malnutrition. So, this study was conducted to determine the outcome of magnesium supplementation in severely malnourished children.

Methodology
This hospital based prospective case-control study was carried out in the Departments of Paediatrics, BSMMU, Dhaka and Ad-din Hospital, Magbazar, Dhaka, from June 2006 to December 2006. Purposively consecutive sixty hospitalized children between 6 to 59 months age, with severe malnutrition were enrolled in the study. Severe malnutrition were defined as per WHO criteria of PEM. After admission detail history, through physical examinations and relevant investigations were collected on a pre-designed semi-structured questionnaire. In physical examination emphasis was given on weight, height and clinical evidence of disturbances in magnesium deficiency. Children were divided randomly into two equal groups, group-I (control) and group-II (case). Group-I patients were treated with F-75/F-100 formula14 along with vitamins and minerals without any magnesium supplementation. Group-II children were treated with F-75/F-100 formula and CMV (combined mineral & vitamins) containing magnesium. One scoop of CMV contains 146 mg of magnesium along with other minerals and vitamins. One scoop of CMV was dissolved in 40 ml of water and then 20 ml of the prepared solution was added to each liter of F-75/F-100 formula. So, each

1. Dr. MD. Ibrahim Khalil, MBBS, MCPS, FCPS, MD; Department of Paediatrics, BSMMU. e-mail: ibrahim.khalil@yahoo.com 2. Dr. Abdullah-Al-Baki, MBBS, MD; Department of Paediatrics, BSMMU. 3. Dr. Naarin Akhter, MBBS, MPH (RCH); Department of Psychiatry, BSMMU, Dhaka. 4. Maj Md. Abdu Samad Al-Azad, MBBS, MCPS, DFM; Department of Forensic Medicine, AFMC. 5. Dr. Forzana Zafreen MBBS, MPH (RCH); Assistant Professor, Department of Community Medicine, Medical College for Women & Hospital, Uttra, Dhaka. 6. Maj Md. Abdul Wahab, MBBS, MD; Assistant Professor, Department of Biochemistry, AFMC, Dhaka. e-mail: wahab947@yahoo.com

JAFMC Bangladesh. Vol 4, No 2 (Dec) 2008
100 ml and 130 ml of F-75/F-100 formula contained 7.3 mg and 9.49 mg of magnesium respectively. Thus an average intake of magnesium was 7.3-14.6 mg/kg/day (0.3-0.6 mmol/kg/day) throughout the initial 12 days of treatment. Each patient of both the groups was daily followed-up to observe the clinical response.

### Table-I: Demographic features of studied subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group-I (n=30)</th>
<th>Group-II (n=30)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (months)</td>
<td>22.14 ± 12.03</td>
<td>23.15 ± 11.60</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>72.32 ± 7.80</td>
<td>70.21 ± 7.82</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>Sex Male (%)</td>
<td>13 (43.33)</td>
<td>16 (53.33)</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>Female (%)</td>
<td>17 (56.67)</td>
<td>14 (46.67)</td>
<td></td>
</tr>
</tbody>
</table>

Note: For Age & Height Unpaired "t" test and for Sex Chi square test were done.

After taking informed written consent from the guardians, under all aseptic precaution 2.5 ml of venous blood sample was collected at admission and 12th day of treatment from each patient of both groups. Serum was separated and preserved at -35°C in different vials until analysis. Serum magnesium was measured in the percentage (%). Statistical analyses were performed by Chi-square and paired & unpaired "t" test and 95% confidence level was taken as level of significance.

### Result

Age range of the children was 6-56 months. Almost equal number of children of either sex was studied in both groups. Age, height and sex distribution of studied children were not significantly (p>0.05) different (table I).

Clinical profile of studied children was shown in table-II. Before treatment diarrhoea was found in 16 (53%) and 22 (73%) children of group-I & II respectively and the difference was not significant (p > 0.05). Vomiting was seen in 21(70%) and 15 (50%) children of group-I & II respectively. After treatment, this was improved completely (100%) in group-II but only 76% cases improved in group-I (p < 0.01). In both the groups, majority of the patients showed irritability which was improved after treatment and magnesium supplemented group showed better improvement.

Poor appetite was noted in 24 (80%) in group-I and 22 (73%) in group-II patients before treatment, which were not significantly (p > 0.05) different. After treatment appetite was improved significantly (p < 0.01) in magnesium supplemented group. Hypotonia was found in all the patients in both the groups before treatment. After magnesium supplementation, hypotonia was improved in most of the cases, 28 (93%) in group-II and only 15 (50%) cases in group-I (p < 0.001). Symmetrical oedema was seen in 17 (56%) patients of group-I and 16(53%) patients of group-II which disappeared completely after treatment and magnesium supplementation showed no change in subsiding oedema. Gastroenteritis was found as the commonest infection in malnourished children, 10 (33%) in group-I and 11 (36%) in group-II followed by pneumonia, oral candidiasis and tuberculosis. Infections were improved after treatment.

Pre-treatment magnesium levels were not significantly (p > 0.05) different between the groups. Post-treatment magnesium values were significantly (p < 0.001) different between the groups (table-III). Magnesium level was significantly improved in group II on 12th day of treatment (p < 0.001).

Before treatment weight was not significantly (p > 0.05)
Table-III: Serum Magnesium level before and after supplementation

<table>
<thead>
<tr>
<th>Serum Magnesium (mg/dL)</th>
<th>Group-I (n=30)</th>
<th>Group-II (n=30)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>1.46 ± 0.25</td>
<td>1.36 ± 0.25</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>Day 12</td>
<td>1.63 ± 0.26</td>
<td>2.06 ± 0.35</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>p value (Day 1 vs. Day 12)</td>
<td>&gt; 0.50</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

Note: Group-I vs. group-II by unpaired 't' test and day-1 vs. day- 12 by paired 't' test.

Table-IV: Effect of Magnesium supplementation on weight of the children

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Group-I (n = 30)</th>
<th>Group-II (n = 30)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td>7.3 ± 1.63</td>
<td>7.2 ± 1.5</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>After oedema subsided</td>
<td>7.2 ± 1.6</td>
<td>7.1 ± 1.4</td>
<td>&gt; 0.50</td>
</tr>
<tr>
<td>Day 12</td>
<td>7.7 ± 1.9</td>
<td>9.6 ± 1.7</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Rate of weight gain (g/kg/day)</td>
<td>8.9 ± 3.5</td>
<td>12.2 ± 6.3</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

Note: Oedema was completely subsided on different days of treatment. Rate of weight gain was calculated by taking weight after edema completely subsided and weight on day 12. Unpaired 't' test between groups and paired 't' test between days.

different between the groups i.e. 7.3 ± 1.63 kg vs 7.21 ± 1.50 kg. After treatment weight was 7.72 ± 1.87 kg vs 9.61 ± 1.71 kg in group-I and group-II respectively. The weight was significantly (p < 0.05) different after treatment in both the groups. The rate of weight gain (g/kg/day) was significantly different in group-I and group-II which were 8.87 ± 3.51 and 12.16 ± 6.32 respectively. Athetoid movement, seizures or convulsion were not observed in any studied child.

Discussion
Diets in population are frequently deficient in micronutrients and magnesium is gaining recognition as a clinically important electrolyte. Mean age of the studied children was 22.14 ± 12.03 months (group I) and 23.15 ± 11.60 months (group II). There was a female preponderance and male female ratio 1:1.06. Similar observation was mentioned by others.

Vomiting is associated with hypomagnesemia. It was improved in all cases of magnesium supplementation (76% vs 100% in group I and group II respectively; and p<0.01). Similar finding was reported by Caddell of Nigeria.

In general, magnesium treated children rapidly acquired a good appetite. In this study, magnesium supplemented children showed significant improvement of appetite. Similar findings were noted by other authors.

Deficiency of magnesium causes generalized hypotonia. Hypotonia was found in all cases of studied children. Significant improvement was observed in magnesium supplemented group. This improvement of tone may be due to replenishment of muscle magnesium pool. Similar observation was reported by others. Nichols et al mentioned that magnesium may play a role in promoting recovery of muscle composition.

Symmetrical oedema was found in about half of the patients of both the groups. Reported study could not find any correlation between magnesium supplemented and non-supplemented group as oedema subsided in PEM children between 4 to 10 days of treatment. Tremor is associated with hypomagnesemia. In this series, tremor was found in 14(23%) which was improved on 12 day of treatment. No correlation was observed with magnesium supplementation.

Mean serum magnesium levels were 1.46 ± 0.25 mg/dL in group I and 1.36 ± 0.25 mg/dL in group II on day 1 before starting treatment. These levels were below normal value of 1.56 mg/dL. After treatment on day 12 these were 1.63 ± 0.26 mg/dL and 2.06 ± 0.35 mg/dL in group I and group II respectively; much improved in magnesium supplemented group. Karla et al found serum magnesium level 1.92 mg/dL before supplementation and 2.23 mg/dL after supplementation. In this series magnesium was as low as 0.8 mg/dL but Montgomery reported serum magnesium levels as low as 1.2 mg/dL.

Before treatment weight was not significantly different between the groups. After treatment, weight gain occurred significantly in both the groups of children. Rate of weight gain was accelerated after magnesium supplementation. In this series, rate of weight gain was 8.87 ± 3.51 gm/kg/day in group-I and 12.16 ± 6.32 gm/kg/day in group-II. This difference was statistically significant. Similar observation was noted by Montgomery.

Conclusion
In this study serum magnesium level was lower than normal in severely malnourished children. Magnesium supplemented group of patients showed better improvement of appetite, reduction of vomiting and hypotonia. The rate of weight gain was highly significant (p < 0.001) in magnesium supplementation group. So, magnesium may be routinely used in the management of malnourished children to hasten recovery.

References


